Company Filing History:

7 out of 212

Cetus Corporation

patents

Cetus Oncology Corporation

patents

4. 1 out of 5,309

Leland Stanford Junior University

patents

Years Active: 1985-2000

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6060068 - Human IL-2 as a vaccine adjuvant (2000-05-09),

2. 5800810 - Human IL-2 as a vaccine adjuvant (1998-09-01),

3. 5643565 - Human IL-2 as a vaccine adjuvant (1997-07-01),

4. 5503841 - Human IL-2 as a vaccine adjuvant (1996-04-02),

5. 5422275 - Protein production at synthetic start site (1995-06-06),

6. 5102872 - Controlled-release formulations of interleukin-2 (1992-04-07),

7. 5100664 - Human IL-2 as a vaccine adjuvant (1992-03-31),

8. 4818769 - Method of controlling stress-related disease in livestock by (1989-04-04),

9. 4794175 - Glucoamylase CDNA (1988-12-27),

10. 4789702 - Feline leukemia virus vaccine (1988-12-06),

11. 4701416 - Feline leukemia virus vaccine plasmids for fusion protein of the gp70 (1987-10-20),

12. 4555486 - Method for using an amino-terminus DNA sequence to synthesize a specific (1985-11-26),

Title: Jack H Nunberg: Innovator in Vaccine Adjuvants

Introduction

Jack H Nunberg is a prominent inventor based in Oakland, CA (US). He has made significant contributions to the field of immunology, particularly in the development of vaccine adjuvants. With a total of 12 patents to his name, Nunberg's work has had a lasting impact on vaccine efficacy and immune response enhancement.

Latest Patents

Among his latest patents, Nunberg has developed methods for enhancing the immune response to vaccination in animals, including humans. His innovative approach involves administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. Additionally, his compositions for enhancing the immune response of an animal to a vaccine utilize IL-2 as an active ingredient, specifically human IL-2.

Career Highlights

Throughout his career, Nunberg has worked with notable companies such as Cetus Corporation and Chiron Corporation. His experience in these organizations has allowed him to refine his expertise in vaccine development and immunology.

Collaborations

Some of his notable coworkers include Michael V Doyle and Arthur D Newell. Their collaborative efforts have contributed to advancements in the field of vaccine research and development.

Conclusion

Jack H Nunberg's innovative work in vaccine adjuvants has significantly advanced the field of immunology. His contributions continue to influence vaccine efficacy and public health.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com